Pfizer to Present Data on Neratinib, Sutent at San Antonio Breast Cancer Symposium

At the San Antonio Breast Cancer Symposium being held this week, Pfizer is planning to present new clinical trial data on neratinib, an investigational pan-ErbB inhibitor in patients with HER2-positive breast cancer, as well as data on the marketed oncologic Sutent (sunitinib malate) in metastatic breast cancer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.